Jardiance.in

CV DEATH MAY BE CLOSER
THAN YOU THINK

Despite advances in care, most patients with
type 2 diabetes die of a CV event.¹

CV: Cardiovascular.
References

1. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H; the WHO Multinational Study Group. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44:S14-S21.

For your type 2 diabetes patients with hypertension,
CAD and dyslipidemia who are on metformin^1,*Choose Jardiance^® early to protect
against the risk of CV death^†

CAD: Peripheral artery disease. CV: Cardiovascular. RRR: Relative risk reduction. HbA1c: Glycated haemoglobin.SGLT2i: Sodium-glucose co-transporter 2 inhibitor. CAD: Coronary artery disease. HR: Hazard ratio. CI: Confidence interval. CVD: Cardiovascular disease. T2DM: Type 2 diabetes mellitus.
^* Adult patients with type 2 diabetes and CAD, PAD, or a history of MI or stroke.^1,2,7
^† 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME^® population for the duration of the trial (HR=0.62; 95% CI: 0.49, 0.77; p<0.001).²
^‡ Hospitalisation for heart failure was a secondary CV outcome in the EMPA-REG OUTCOME^® trial (HR=0.65; 95% CI: 0.50, 0.85).¹,7
^§ In adult patients of T2DM with CVD.

References

1. Jardiance^® approved prescribing information, Boehringer Ingelheim India, Version 19^th Nov 2018.
2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME^® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol. 2018;71(3):364-367.
4. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138(17):1904-1907.
5. Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther. 2017;34(7):1707-1726.
6. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc. 7. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME^®). Cardiovasc Diabetol. 2014;13(102).

CAD: Coronary artery disease. CV: Cardiovascular. RRR: Relative risk reduction. ACEi: Angiotensin-converting enzyme inhibitor ARB: Angiotensin II receptor blocker. PAD: Peripheral artery disease. HbA1c: Glycated haemoglobin. HR: Hazard ratio. CI: Confidence interval.
^* Adult patients with insufficiently controlled type 2 diabetes (HbA1c 7-10%) and established CV disease including CAD, PAD, or a history of MI or stroke.^1,2,5
^† 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME^® population for the duration of the trial (HR=0.62; 95% CI: 0.49, 0.77; p<0.001).²
^‡ Pooled data from 10-mg and 25-mg doses of Jardiance^®; both doses showed a comparable reduction in the risk of CV death.^1,3

References

1. Jardiance^® approved prescribing information, Boehringer Ingelheim India, Version 19^th Nov 2018.
2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME^® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2016;37(29):2315-2381.
4. Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol. 2018;71(3):364-367.
5. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME^®). Cardiovasc Diabetol. 2014;13(102).

CV: Cardiovascular. HbA1c: Glycated haemoglobin. RRR: Relative risk reduction. HR: Hazard ratio. CI: Confidence interval.
^* A post-hoc analysis of data from the EMPA-REG OUTCOME^® Trial by baseline HbA1c subgroups.² EMPA-REG OUTCOME^® was not powered to show differences between subgroups.^1,3
^† 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME^® population for the duration of the trial (HR=0.62; 95% CI: 0.49, 0.77; p<0.001).¹
^‡ Hazard ratios are related to CV death: HbA1c <7% HR=0.30 (95% CI: 0.12, 0.80); HbA1c 7% to <8% HR=0.59 (95% CI: 0.42, 0.83); HbA1c 8% to <9% HR=0.67 (95% CI: 0.45, 0.99); HbA1c ≥9% HR=0.76 (95% CI: 0.44, 1.31); p=0.41 for interaction.²

References

1. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME^® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
2. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138(17):1904-1907.
3. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME^®). Cardiovasc Diabetol. 2014;13(102).

GLP-1: Glucagon-like peptide-1. SGLT2i: Sodium-glucose co-transporter 2 inhibitor. ADA: American Diabetes Association. EASD: European Association for the Study of Diabetes. CVD: Cardiovascular disease.

References

1. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.

CAD: Coronary artery disease. RRR: Relative risk reduction. ACEi: Angiotensin-converting enzyme inhibitor. ARB: Angiotensin II receptor blocker. HF: Heart failure. HbA1c: Glycated haemoglobin. HR: Hazard Ratio. CI: Confidence interval.
^* Adult patients with type 2 diabetes and CAD, PAD, or a history of MI or stroke.^1,2,3
^† Hospitalisation for heart failure was a secondary CV outcome in the EMPA-REG OUTCOME^® trial (HR=0.65; 95% CI: 0.50, 0.85).^1,3
^‡ Pooled data from 10-mg and 25-mg doses of Jardiance^®; both doses showed a comparable reduction in the risk of hospitalisation for heart failure.²

References

1. Jardiance^® approved prescribing information, Boehringer Ingelheim India , Version 19th Nov 2018.
2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME^® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME^®). Cardiovasc Diabetol. 2014;13(102).

CV: Cardiovascular. CAD: Coronary artery disease. PAD: Peripheral artery disease. MI: Myocardial infarction.
^* Adult patients with type 2 diabetes and CAD, PAD, or a history of MI or stroke.^1,2,6 ^† Hospitalisation for heart failure was a secondary CV outcome in the EMPA-REG OUTCOME^® trial.⁶

References

1. Jardiance^® approved prescribing information, Boehringer Ingelheim India, Version 19^th Nov 2018.
2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME^® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. JANUVIA [summary of product characteristics]. Hertfordshire, United Kingdom: Merck Sharp & Dohme Ltd.; June 2018.
4. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242.
5. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
6. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME^® sitagliptin). Cardiovasc Diabetol. 2014;13(102).

THE ONLY SGLT2I TO RECEIVE THE PRESTIGIOUS PRIX GALIENAWARD IN HISTORY

Worldwide, the award is regarded as the equivalent of the Nobel Prize in the field of pharmaceutical research and innovation.¹

References

1. Data on file. Boehringer Ingelheim. Available at https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2018-prix-galien-international-award-recipents-300756911.html. Last accessed on 17th Dec 2018.

LIVE WEBINAR

4:30- 5:30 pm 27/06/2020

Cardio Renal Metabolic Continuum and Mortality in T2DM

Speakers: Padmashri Dr. V. Mohan & Dr. Tiny Nair

In type 2 diabetes patients with established CV disease,*
Choose JARDIANCE^® to reduce the risk of CV death on top of standard of care^1,2

reduced cv death

Early and sustained reduction in CV death^2-4

1. Jardiance^® prescribing information, Boehringer-Ingelheim (India) Pvt Ltd. 2^nd Feb, 2018.

2. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOM^®). Cardiovasc Diabetol. 2014;13(102). doi:10.1186/1475-2840-13-102.

3. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.

4. Van de Borne, et al. Heart failure hospitalisation or cardiovascular death with empagliflozin in patients with type 2 diabetes and high cardiovascular risk: analysis over time in EMPA-REG OUTCOE^®. Poster no. 1119 presented at: European Association for the Study of Diabetes. Annual Meeting; September 12-16, 2016; Munich, Germany.

(*Established CV Disease includes Coronary Artery Disease, or Peripheral Arterial Disease, or Myocardial Infarction, or Stroke)

Only OAD approved to reduce the risk of CV Death
in adult patients of T2DM with established CVD¹

38%

Reduction in risk of

CV Death in T2D patients

with established CVD²

1. Jardiance^® prescribing information. Boehringer-Ingelheim (India) Pvt Ltd. 2^nd Feb, 2018.
2. Zinman B, et al. N Engl J Med. 2015;373(22):2117-28.

In a subgroup analysis* from EMPA-REG OUTCOME^®
Reduction in risk of CV death for JARDIANCE^® was independent of baseline HbA1c^1,2

CONSISTENT ACROSS HbA1c

CV death
benefit outcome

CV death reduction was generally
consistent across baseline HbA1c³

Subgroup analysis included:

HbA1c <7%^†
HbA1c 7% to <8%^†
HbA1c 8% to <9%^†
HbA1c ≥9%^†

1. Jardiance^® prescribing information, Boehringer-Ingelheim (India) Pvt Ltd. 2^nd Feb, 2018.

2. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME^®). Cardiovasc Diabetol. 2014;13(102). doi:10.1186/1475-2840-13-102.

3. Inzucchi SE, Fitchett D, Wanner C, et al. Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME^®. Poster no. 916 presented at: 53rd Annual Meeting of the European Association for the Study of Diabetes; 11-15 September 2017; Lisbon, Portugal.

"A post-hoc analysis of data from the EMPA-REG OUTCOME^® Trial by baseline HbA1c subgroups.
EMPA-REG OUTCOME^® was not powered to show differences between subgroups.

Only Empagliflozin and Liraglutide have Level A evidence-based recommendation for reduction in major adverse CV events and/or CV death, in patients of T2DM with established CVD¹

Recommendation for patients with T2DM and established atherosclerotic CVD¹

1. Adapted from: American Diabetes Association. Standards of Medical Care in Diabetes 2018. Diabetes Care. 2018; 41(Suppl 1):s1 – s153